AnaCardio AB is a clinical-stage biopharmaceutical company focused on developing innovative drugs to treat heart failure, a condition that affects millions globally. The company is pioneering the development of novel inotropic agents that leverage the ghrelin signaling pathway to enhance cardiac contractility. This unique mechanism aims to improve the heart's ability to pump blood without causing common adverse effects associated with traditional treatments, such as tachycardia, arrhythmia, or hypotension. By targeting the underlying causes of heart failure, particularly in patients with reduced ejection fraction, AnaCardio seeks to provide safer and more effective treatment options that can enhance organ function, quality of life, and reduce hospitalization rates.

The lead product in AnaCardio's pipeline, AC01, is an oral small-molecule ghrelin peptidomimetic designed to act as a contractile agent for heart failure patients. Recent clinical studies, including the GOAL-HF1 study, have demonstrated the safety and pharmacokinetic properties of AC01, with promising results that support its advancement to further phases of clinical trials. The company is committed to addressing the significant unmet needs in heart failure treatment, particularly for patients with chronic and advanced stages of the disease, by developing therapies that effectively improve cardiac function without increasing oxygen consumption or mortality risks.

Sweden

AnaCardio AB is a privately held Swedish, clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. Its lead program AC01 is planned to enter phase 2 clinical development in heart failure patients in 2022. You can find more information about AnaCardio at www.anacardio.com.

AnaCardio

Company Details